Skip to main content
Contact Us
Subscribe
E-Edition
71°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Karuna Therapeutics Inc
(NQ:
KRTX
)
329.83
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Karuna Therapeutics Inc
< Previous
1
2
3
4
5
Next >
UBS Stock Price Prediction: Why This Analyst Says UBS Is a ‘Buy’
March 20, 2023
UBS (UBS) stock is a hot topic among traders on Monday with one analyst offering a new rating for the financial company's shares.
Via
InvestorPlace
Karuna Therapeutics Says It One Step Closer To Potential Treatment Option After Encouraging Schizophrenia Data
March 20, 2023
Via
Benzinga
Why Is Karuna Therapeutics (KRTX) Stock Moving Today?
March 20, 2023
Karuna Therapeutics (KRTX) stock is on the move Monday after releasing positive results from a Phase 3 clinical trial for KarXT.
Via
InvestorPlace
Karuna Surges To Three-Month High On Another Win In Schizophrenia
March 20, 2023
The company is soon planning to ask for FDA approval of KarXT.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023
March 08, 2023
Via
Benzinga
The Latest Analyst Ratings for Karuna Therapeutics
March 02, 2023
Via
Benzinga
Looking Into Karuna Therapeutics's Return On Capital Employed
February 28, 2023
Via
Benzinga
Analyst Expectations for Karuna Therapeutics's Future
January 27, 2023
Via
Benzinga
Ciena, Apple And 3 Stocks To Watch Heading Into Monday
March 06, 2023
With US futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Target To Rally 20%? Here Are 10 Other Analyst Forecasts For Thursday
March 02, 2023
Bernstein raised the price target for Okta, Inc. (NASDAQ: OKTA) from $80 to $92. Bernstein analyst Peter Weed maintained a Market Perform rating. Okta shares jumped 16.2% to $83.00 in pre-market...
Via
Benzinga
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
February 03, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
January 27, 2023
Via
Benzinga
5 Analysts Have This to Say About Karuna Therapeutics
December 09, 2022
Via
Benzinga
What 5 Analyst Ratings Have To Say About Karuna Therapeutics
December 09, 2022
Via
Benzinga
Where Karuna Therapeutics Stands With Analysts
December 09, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Expert Ratings for Karuna Therapeutics
December 09, 2022
Via
Benzinga
Why Karuna Therapeutics Shares Are Trading Sharply Lower
December 06, 2022
Karuna Therapeutics Inc (NASDAQ: KRTX) shares are trading lower by 11.63% to $200.56 going into the close of Tuesday's session after the company announced a CEO transition. What Happened?
Via
Benzinga
Looking Into Karuna Therapeutics's Return On Capital Employed
November 23, 2022
Via
Benzinga
My 3 Top Biotech Stock Picks for 2023
November 22, 2022
Biotech stocks are set to shine in 2023.
Via
The Motley Fool
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
November 16, 2022
Neurodegenerative disorders could mean big bucks for some biotechs.
Via
Investor's Business Daily
Karuna Therapeutics: Q3 Earnings Insights
November 03, 2022
Karuna Therapeutics (NASDAQ:KRTX) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
What 12 Analyst Ratings Have To Say About Karuna Therapeutics
November 01, 2022
Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
12 Analysts Have This to Say About Karuna Therapeutics
November 01, 2022
Within the last quarter, Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Upgrades
Via
Benzinga
2 On-Fire Biotech Stocks That Are Crushing the Bear Market
October 31, 2022
The biotech sector is down this year, but these two biopharmaceutical stocks have delivered strong returns.
Via
The Motley Fool
Opportunities In Large Cap Growth And Small Cap
October 20, 2022
The third quarter was true
Via
Talk Markets
Biotech Stocks Well-Positioned For The Fourth Quarter
October 12, 2022
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.
Via
Talk Markets
Where Karuna Therapeutics Stands With Analysts
September 29, 2022
Over the past 3 months, 12 analysts have published their opinion on Karuna Therapeutics (NASDAQ:KRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
7 Momentum Stocks to Buy Now for Extraordinary Gains
September 26, 2022
Momentum stocks aren't as risky as some say, and these winning stocks are strong examples for investors to consider.
Via
InvestorPlace
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.